Antibody-Drug Conjugates: The DXd Franchise and Competitor Landscape | Oncology Modality Intelligence

Description

List of Tables

The antibody-drug conjugate is the first oncology modality in decades in which a Japanese company holds the defining platform. Daiichi Sankyo's DXd technology - a topoisomerase I payload with a cleavable linker and high drug-to-antibody ratio - sits inside Enhertu, which in the space of five years moved from a single salvage indication to a therapy spanning HER2-positive, HER2-low, and HER2-ultralow breast cancer, gastric cancer, lung cancer, and tumor-agnostic use. Japan is simultaneously the franchise's home market, its development engine, and an early readout on how a health system absorbs a fast-expanding ADC label.

The tension runs on three tracks. Commercially, Enhertu's breadth invites the pricing system's response: Japan's market-expansion repricing rules were built for exactly this situation, and each indication extension renews the question of how value is shared between innovator and payer. Competitively, the DXd franchise is no longer alone - Gilead's Trodelvy, Pfizer's Seagen portfolio, AbbVie's Elahere, and a deep Chinese ADC pipeline led by Kelun-Biotech, RemeGen, Hengrui, and DualityBio are contesting the same targets, while Merck's sweeping DXd collaboration and AstraZeneca's co-development role complicate the alliance map. Clinically, the movement of ADCs into earlier lines and the HER2-low reclassification of disease strain diagnostic infrastructure and sequencing conventions in ways Japan's guidelines are still absorbing.

This report maps the DXd franchise and its competitive field with Japan as the focal market. It walks through the platform science, Enhertu's indication-by-indication development and approval record, Datroway's entry as the first TROP2 ADC in Japan, and the pipeline assets behind them - patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan. Chapters cover pivotal trial programs, Japan regulatory and pricing mechanics, companion diagnostics, manufacturing and supply, competitor programs asset by asset, and the deal history that priced the platform.

The report serves oncology BD teams benchmarking assets against DXd, investors tracking franchise durability and repricing exposure, competitors planning Japan strategy, and diagnostics firms sizing the HER2-low and TROP2 testing opportunity. Each chapter closes with what the evidence does and does not yet settle.

Scope and Coverage: The report covers DXd-platform ADCs and competing ADC programs relevant to Japan across breast, gastric, lung, and other solid tumors, including trial programs, PMDA and NHI status, diagnostic requirements, and partnering history. It profiles Daiichi Sankyo, AstraZeneca, Merck, Gilead, Pfizer, AbbVie, Roche, and leading Chinese ADC developers.

Report Highlights:

Traces Enhertu's indication expansion in Japan and the trial programs behind each label
Profiles Datroway's Japan entry and the TROP2 ADC competitive field
Covers pipeline DXd assets: patritumab, ifinatamab, and raludotatug deruxtecan
Maps the Daiichi Sankyo-AstraZeneca and Daiichi Sankyo-Merck alliance structures
Analyzes Japan pricing exposure under market-expansion repricing rules
Benchmarks competitor ADCs from Gilead, Pfizer, AbbVie, Roche, and Chinese developers

Product Code: JPH-026

Table of Content

1. Executive Summary

2. Antibody-Drug Conjugates: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Daiichi Sankyo (JP) - originator of the DXd ADC platform and the Enhertu franchise
AstraZeneca (UK) - global co-development and co-commercialization partner for Enhertu and Datroway
Merck & Co (US) - DXd ADC collaboration partner with Daiichi Sankyo
Gilead Sciences (US) - Trodelvy (sacituzumab govitecan) TROP2 ADC competitor
Pfizer (US) - Seagen ADC portfolio including Padcev
AbbVie (US) - Elahere FR-alpha ADC via the ImmunoGen acquisition
Roche (CH) - Kadcyla and Polivy ADCs; HER2 franchise defense
ADC Therapeutics (CH) - Zynlonta CD19 ADC
Byondis (NL) - trastuzumab duocarmazine HER2 ADC
Kelun-Biotech (CN) - sacituzumab tirumotecan; Merck-partnered ADC pipeline
RemeGen (CN) - disitamab vedotin HER2 ADC
Hengrui (CN) - broad ADC pipeline including HER2 and TROP2 assets
DualityBio (CN) - BioNTech-partnered HER2 and B7-H3 ADCs

Product Code: JPH-026

List of Tables

Table 1. DXd ADC Platform: Payload, Linker, and Drug-to-Antibody Design Features
Table 2. Daiichi Sankyo ADC Portfolio: Approved and Pipeline Assets Overview
Table 3. Enhertu (Trastuzumab Deruxtecan): Mechanism and Molecular Design
Table 4. Enhertu Japan Approval History by Indication and Year
Table 5. DESTINY-Breast01 Through DESTINY-Breast06: Trial Designs and Populations
Table 6. DESTINY-Breast11 and DESTINY-Breast12: Early-Line and Brain-Metastasis Programs
Table 7. DESTINY-Gastric Trial Series: Japan-Led Study Designs
Table 8. DESTINY-Lung01 and DESTINY-Lung02: HER2-Mutant NSCLC Programs
Table 9. DESTINY-PanTumor02 and Tumor-Agnostic Development Strategy
Table 10. DESTINY-CRC Programs in HER2-Expressing Colorectal Cancer
Table 11. Enhertu Combination Development: Immunotherapy and Endocrine Pairings
Table 12. Interstitial Lung Disease Management in Enhertu Programs: Protocol Frameworks
Table 13. Datroway (Datopotamab Deruxtecan): Target, Design, and Japan Approval
Table 14. TROPION-Breast and TROPION-Lung Trial Program Structures
Table 15. Patritumab Deruxtecan (HER3-DXd): HERTHENA Program Designs
Table 16. Ifinatamab Deruxtecan (I-DXd): IDeate Programs in Small Cell Lung Cancer
Table 17. Raludotatug Deruxtecan (R-DXd): CDH6 Program Overview
Table 18. Daiichi Sankyo-AstraZeneca Collaboration: Structure and Scope
Table 19. Daiichi Sankyo-Merck DXd Collaboration: Asset Coverage and Terms Framework
Table 20. Alliance Governance and Profit-Sharing Mechanics for Enhertu
Table 21. Gilead Trodelvy (Sacituzumab Govitecan): Program and Japan Status
Table 22. ASCENT, TROPiCS-02, and EVER-132-002: Trodelvy Trial Designs
Table 23. Pfizer Seagen ADC Portfolio: Padcev and Pipeline Assets
Table 24. EV-302 and Padcev Combinations: Program Structure
Table 25. AbbVie Elahere (Mirvetuximab Soravtansine): FR-Alpha ADC Program
Table 26. Roche Kadcyla and Polivy: Legacy ADC Franchise Position
Table 27. ADC Therapeutics Zynlonta: CD19 ADC Program
Table 28. Byondis Trastuzumab Duocarmazine: TULIP Program
Table 29. Kelun-Biotech Sacituzumab Tirumotecan: OptiTROP Programs and Merck Partnership
Table 30. RemeGen Disitamab Vedotin: HER2 ADC Program in China and Beyond
Table 31. Hengrui ADC Pipeline: HER2 and TROP2 Assets
Table 32. DualityBio DB-1303 and BioNTech-Partnered Programs
Table 33. China ADC Developer Landscape: Licensing-Out Activity Map
Table 34. HER2-Low and HER2-Ultralow Classification: Testing Implications in Japan
Table 35. TROP2 Biomarker Testing Status for Datroway Patient Selection
Table 36. PMDA Review Pathways Used by ADC Applications in Japan
Table 37. NHI Pricing Mechanics for ADCs and Market-Expansion Repricing Exposure
Table 38. Enhertu Pricing History in Japan: Listing and Revision Record
Table 39. Cost-Effectiveness Assessment Treatment of Enhertu in Japan
Table 40. ADC Manufacturing and Supply-Chain Structure for the DXd Franchise
Table 41. Capacity Planning for Payload and Linker Production
Table 42. Japan ADC Treatment Infrastructure: Infusion and Monitoring Requirements
Table 43. Hospital and Prescriber Adoption Framework for New ADC Indications
Table 44. Sequencing Questions Raised by Multi-Indication ADC Labels
Table 45. ADC Pipeline Attrition: Discontinued Programs and Lessons
Table 46. Payload and Linker Innovation Beyond DXd: Emerging Designs
Table 47. Bispecific and Immune-Stimulating ADC Concepts in Development
Table 48. Competitive Positioning Matrix: DXd vs Rival ADC Platforms
Table 49. Scenario Framework: Enhertu Franchise Under Pricing and Competition Pressure
Table 50. Analytical Appendix: Trial Registries, PMDA Sources, and Deal Databases

List of Figures

Figure 1. DXd Platform Architecture: Antibody, Linker, and Payload
Figure 2. Daiichi Sankyo ADC Portfolio Map
Figure 3. Enhertu Indication Expansion Timeline in Japan
Figure 4. DESTINY-Breast Program Family Tree
Figure 5. DESTINY-Gastric Japan-Led Program Map
Figure 6. DESTINY-Lung and DESTINY-PanTumor Program Structures
Figure 7. Enhertu Combination Strategy Diagram
Figure 8. ILD Monitoring and Management Protocol Flow
Figure 9. Datroway Molecular Design and Japan Entry Timeline
Figure 10. TROPION Program Family Tree
Figure 11. HERTHENA Program Structure for Patritumab Deruxtecan
Figure 12. IDeate Program Structure for Ifinatamab Deruxtecan
Figure 13. R-DXd CDH6 Program Positioning
Figure 14. Daiichi Sankyo-AstraZeneca Alliance Structure Diagram
Figure 15. Daiichi Sankyo-Merck Collaboration Asset Map
Figure 16. Trodelvy Program and Japan Status Map
Figure 17. Pfizer Seagen ADC Portfolio Tree
Figure 18. Elahere and FR-Alpha ADC Program Diagram
Figure 19. Roche Legacy ADC Franchise Map
Figure 20. China ADC Developer Licensing-Out Network
Figure 21. Kelun-Merck Partnership Structure
Figure 22. RemeGen Disitamab Vedotin Program Map
Figure 23. Hengrui and DualityBio Pipeline Trees
Figure 24. HER2-Low Reclassification Impact on Testing Workflow
Figure 25. TROP2 Testing Pathway for Datroway
Figure 26. PMDA Review Pathway Map for ADCs
Figure 27. NHI Pricing and Market-Expansion Repricing Mechanics
Figure 28. Enhertu Japan Pricing Timeline
Figure 29. Cost-Effectiveness Assessment Flow for Oncology Drugs
Figure 30. DXd Manufacturing and Supply-Chain Diagram
Figure 31. Payload-Linker Capacity Planning Framework
Figure 32. Infusion Infrastructure Requirements for ADC Delivery
Figure 33. Prescriber Adoption Pathway for New Indications
Figure 34. Sequencing Decision Framework for Multi-Indication ADCs
Figure 35. ADC Pipeline Attrition Map
Figure 36. Payload and Linker Innovation Landscape
Figure 37. Bispecific ADC Concept Diagram
Figure 38. Competitive Positioning Map: ADC Platforms
Figure 39. Scenario Tree: Enhertu Franchise Pressure Paths
Figure 40. Biomarker-Defined Patient Funnel for ADC Indications
Figure 41. Japan vs US and EU ADC Approval Sequence Comparison
Figure 42. Deal History Timeline for the DXd Platform
Figure 43. ADC Safety Management Infrastructure in Japanese Hospitals
Figure 44. Line-of-Therapy Migration Pattern for ADC Labels
Figure 45. Companion Diagnostic Partnership Map for ADCs
Figure 46. China ADC Trial Landscape: Indication Coverage Map
Figure 47. Investor KPI Dashboard for the DXd Franchise
Figure 48. Competitor Response Options to DXd Expansion
Figure 49. Synthesis: Durability Conditions for DXd Leadership
Figure 50. Report Roadmap: Chapter Linkages to Reader Decisions

Antibody-Drug Conjugates: The DXd Franchise and Competitor Landscape | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Antibody-Drug Conjugates: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures